Toll Free: 1-888-928-9744

Lexicon Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Lexicon Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Lexicon Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Lexicon Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lexicon Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Lexicon Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Lexicon Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Lexicon Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

- Evaluate Lexicon Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Lexicon Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Lexicon Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Lexicon Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lexicon Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Lexicon Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Lexicon Pharmaceuticals, Inc. Snapshot 5
Lexicon Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Lexicon Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Lexicon Pharmaceuticals, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Lexicon Pharmaceuticals, Inc. - Pipeline Products Glance 13
Lexicon Pharmaceuticals, Inc. - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
Lexicon Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Lexicon Pharmaceuticals, Inc. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Lexicon Pharmaceuticals, Inc. - Drug Profiles 17
telotristat etiprate 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
LX-1033 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
LX-2931 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
sotagliflozin 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
LX-7101 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
LX-2761 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
S100-A8 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Lexicon Pharmaceuticals, Inc. - Pipeline Analysis 28
Lexicon Pharmaceuticals, Inc. - Pipeline Products by Target 28
Lexicon Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 29
Lexicon Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 30
Lexicon Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 31
Lexicon Pharmaceuticals, Inc. - Recent Pipeline Updates 32
Lexicon Pharmaceuticals, Inc. - Dormant Projects 39
Lexicon Pharmaceuticals, Inc. - Company Statement 41
Lexicon Pharmaceuticals, Inc. - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44
List of Tables
Lexicon Pharmaceuticals, Inc., Key Information 5
Lexicon Pharmaceuticals, Inc., Key Facts 5
Lexicon Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8
Lexicon Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9
Lexicon Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10
Lexicon Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 11
Lexicon Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12
Lexicon Pharmaceuticals, Inc. - Phase III, 2014 13
Lexicon Pharmaceuticals, Inc. - Phase II, 2014 14
Lexicon Pharmaceuticals, Inc. - Phase I, 2014 15
Lexicon Pharmaceuticals, Inc. - Preclinical, 2014 16
Lexicon Pharmaceuticals, Inc. - Pipeline by Target, 2014 28
Lexicon Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 29
Lexicon Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 30
Lexicon Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 31
Lexicon Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 32
Lexicon Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 39
Lexicon Pharmaceuticals, Inc., Subsidiaries 42 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify